Alzheimer’s and other neurodegenerative diseases have tremendous unmet therapeutic and diagnostic need, and we are excited to be in a position to address these challenges with our platform. IsoPlexis Corporation , a venture-capital funded life sciences company developing an innovative cellular response analysis platform to measure the proteomic function of individual cells in patients, today announced it was recently awarded a competitive Phase I Small Business Innovation Research grant from the National Institute on Aging of the National Institutes of Health to develop a system to analyze trafficking leukocytes’ highly multiplexed proteomic responses in patients with Alzheimer’s disease.